Editas Medicine, Inc. · NASDAQ:EDIT
Editas Medicine — American Heart Association Scientific Sessions 2026
15 slides from Editas Medicine's conference presentation, November 2026

Slide 1: EDIT-401: In Vivo Gene Editing to Enhance LDLR Function for Durable LDL-C Reduction
EDIT-401: IN VIVO GENE EDITING TO ENHANCE LDLR FUNCTION FOR DURABLE LDL-C REDUCTION Daniel Ory, MD | Chief Medical Officer, Editas Medicine #ScientificSessions26

Slide 2: Disclosure Slide
DISCLOSURE SLIDE This presentation contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words ‘‘anticipate,’’ ‘‘believe,’’ ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ ‘‘in tend,’’ ‘‘may,’’ ‘‘plan,’’ ‘‘potential,’’

Slide 3: Editas Medicine: A Differentiated Genetic Medicine Engine
EDITAS MEDICINE: A DIFFERENTIATED GENETIC MEDICINE ENGINE Accessible, Durable Medicines: Single-dose, Lifelong Benefit Harness gene editing to Challenge the unlock new possibilities, status quo and change Establish a Realize the such as increasing levels the course of disease New Unique of disease-m

Slide 4: Lower LDL-C Is Better in Patients with ASCVD
LOWER LDL-C IS BETTER IN PATIENTS WITH ASCVD Continuous relationship between LDL-C lowering and reduced risk of CV events2 • LDL-C is the foundational marker of CV event probability (%) ASCVD risk,1 and risk of CV events continues to decrease with lower LDL-C levels2,3 • Guidelines recommend aggress

Slide 5: Therapeutic Strategy of LDLR Upregulation Is Informed by Human Genetics
THERAPEUTIC STRATEGY OF LDLR UPREGULATION FOR LDL-C REDUCTION IS INFORMED BY HUMAN GENETICS Seven Icelandic family members were identified as carriers of partial LDLR 3' UTR deletion1 Similar deletions have been identified in families in France and the UK 2 Plasma LDL-C levels1 Impact on carriers1 3

Slide 6: EDIT-401 Uses a Differentiated Mechanism of Action to Reduce LDL-C
EDIT-401 USES A DIFFERENTIATED MECHANISM OF ACTION TO REDUCE LDL-C EDIT-401 therapeutic strategy for LDLR upregulation • LDLR upregulation strategy targets functional alleles rather than correcting a deficient gene • LDLR upregulation is achieved by disrupting negative regulatory elements of the LDL

Slide 7: Single Dose of EDIT-401 Evaluated Across NHP Studies
SINGLE DOSE OF EDIT-401 EVALUATED ACROSS NHP STUDIES PD/Biomarker Endpoints NHP Study Design 1. LDL-C levels 2. Lp(a) levels 3. ApoB levels Vehicle Control Safety Endpoints 1. Tolerability assessment Single Dose 2. Liver function test 3. Histopathology EDIT-401 Dose Range: PK/Biodistribution EDIT-40

Slide 8: Robust, Dose-Dependent, and Durable LDL-C Reduction Following a Single Dose
ROBUST, DOSE-DEPENDENT, AND DURABLE LDL-C REDUCTION FOLLOWING A SINGLE DOSE OF EDIT-401 ≥90% mean LDL-C reduction at 10 months Vehicle 1.5 mg/kg 2 mg/kg 3 mg/kg 40 (n=4) (n=4) (n=4) (n=4) (mean % reduction from baseline) 30 20 10 0 -10 -20 LDL-C -30 -40 -50 -60 -70 -80 -90 -100 7 10 1 2 3 4 5 6 8 9

Slide 9: Single Dose of EDIT-401 Lowers Multiple Atherogenic Lipoproteins
SINGLE DOSE OF EDIT-401 LOWERS MULTIPLE ATHEROGENIC LIPOPROTEINS ~90% mean Lp(a) reduction at 3 months ~90% mean ApoB reduction at 3 months Vehicle 1.5 mg/kg 3 mg/kg 5 mg/kg 60 Vehicle 1.5 mg/kg 3 mg/kg 5 mg/kg (mean % reduction from baseline) 60 (n=8) (n=8) (n=8) (n=8) (mean % reduction from baseli

Slide 10: No Adverse Liver Findings Following Single Dose of EDIT-401
NO ADVERSE LIVER FINDINGS FOLLOWING SINGLE DOSE OF EDIT-401 • Transient ALT elevations • No bilirubin elevations • No histopathologic changes Mean (SD) ALT Mean (SD) Bilirubin 600 1.0 Vehicle Vehicle 1.5 mg/kg 0.9 1.5 mg/kg 500 0.8 0.7 400 0.6 Units/L Units/L 300 0.5 0.4 200 0.3 0.2 100 0.1 0 0.0 D8

Slide 11: EDIT-401 Provides Targeted Delivery to the Liver with No Evidence of Genotoxicity
EDIT-401 PROVIDES TARGETED DELIVERY TO THE LIVER WITH NO EVIDENCE OF GENOTOXICITY EDIT-401 delivers liver-targeted editing ✱✱✱✱ 25% Vehicle • High delivery to hepatocytes with 20% 1.5 mg/kg undetectable Cas9 mRNA in 15% oocytes* % indels • No off-target editing detected in 10% a panel of ~1500 candi

Slide 12: Phase 1/2 Study Design to Evaluate Safety and Efficacy of EDIT-401
PHASE 1/2 STUDY DESIGN TO EVALUATE SAFETY AND EFFICACY OF EDIT-401 FOR LOWERING LDL-C LONG-TERM PART 1 | 2-year follow-up PART 2 | 2-year follow-up EXTENSION Dose ranging & safety study Dose expansion & efficacy study Single ascending IV dose 3:1 randomization (n=20) Adults with HeFH Up to 6 cohorts

Slide 13: Conclusions
CONCLUSIONS • EDIT-401 has demonstrated dose-dependent mean reductions of ~90% in LDL-C, ApoB, and Lp(a), and a consistent safety profile in non-clinical studies to date • EDIT-401 presents a potential best-in-class, one-time treatment opportunity for patients with hypercholesterolemia to reduce LDL

Slide 14: Thank You
THANK YOU #ScientificSessions26

Slide 15: Acknowledgments
ACKNOWLEDGMENTS Nonclinical Development Discovery Genomics & Bioinformatics Clinical/Program Parth Amin Luis Agosto Nassim Ajami Management Jonathan Carey Ameya Apte Jim Bochicchio Thrusha Chauhan Ruhong Dong Linda Burkly Meredith Chamberlin Larissa Collins Anshul Gupta Benjamin Diner Samira Ibrahim
Source: company website
More decks from Editas Medicine, Inc.
Investor Presentation (June 2026)17 slides · June 2026
TIDES 202620 slides · May 14, 2026
ASGCT 29th Annual Meeting 202620 slides · May 2026
ASGCT 28th Annual Meeting 20258 slides · May 2025
Investor Presentation (February 2025)20 slides · February 2025
2025 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR18 slides · February 2025